Table 1. Baseline characteristics in 1,960 patients.
| Age (years) | 57.8 ± 11.5 |
| Sex (male) | 1020 (52%) |
| Weight (kg) | 75.2 ± 15.8 |
| BMI (kg/m2) | 28.3 ± 4.9 |
| BMI categories | |
| <24 | 17.6% |
| ≥24 –<27 | 26.0% |
| ≥27 –<30 | 24.9% |
| ≥30 –<35 | 22.3% |
| ≥35 | 9.2% |
| HbA1c (%) | 8.8 ± 1.4 |
| HbA1c distribution | |
| <7% | 5.8% |
| ≥7% –<8% | 25.1% |
| ≥8% –<9% | 31.4% |
| >9% –≤10% | 19.6% |
| >10% | 18.1% |
| FPG (mg/dL) | 173.0 ± 53.9 |
| SBP (mmHg) | 136.6 ± 17.6 |
| DBP (mmHg) | 77.8 ± 11.3 |
| Total cholesterol (mg/dL) | 164.3 ± 36.0 |
| Triglycerides (mg/dL) | 171.2 ± 133.6 |
| LDL-C (mg/dL) | 89.8 ± 27.8 |
| HDL-C (mg/dL) | 44.8 ± 13.5 |
| Medical history | |
| Hypertension | 60.5% |
| CAD | 7.8% |
| Cerebrovascular disease | 1.7% |
| PAD | 7.4% |
| Heart failure | 2.6% |
| Nephropathy | 34.6% |
| Retinopathy | 10.7% |
| Neuropathy | 14.1% |
| Antihyperglycemic therapy | |
| Metformin | 92.4% |
| Sulfonylurea | 70.7% |
| DPP4 inhibitor | 53.5% |
| Meglitinide | 3.0% |
| α-glucosidase inhibitor | 16.7% |
| Thiazolidinedione | 26.6% |
| GLP-1 RA | 3.0% |
| Insulin | 29.5% |
| Number of antihyperglycemic drug prior to dapagliflozin | |
| Monotherapy | 11.9% |
| Dual therapy | 38.2% |
| Triple therapy | 36.2% |
| >3 drugs combination | 13.8% |
| Manner of dapagliflozin initiation | |
| Add-on | 905 (46.2%) |
| Switch | 1055 (53.8%) |
| Dosage of dapagliflozin | |
| Dapagliflozin 5 mg | 413 (21.1%) |
| Dapagliflozin 10 mg | 1547 (78.9%) |
| Antihypertensive therapy | 61.7% |
| ACEI or ARB | 49.6% |
| β-blocker | 21.1% |
| Calcium channel blocker | 30.9% |
| Diuretic | 11.3% |
| Others | 3.0% |
| Lipid-lowering therapy | 74.5% |
| Statin | 68.6% |
| Fibrate | 9.7% |
| Niacin | 2.3% |
| Ezetimibe | 9.6% |
| Antithrombotic therapy | |
| Antiplatelet | 22.5% |
| Anticoagulant | 2.1% |
Notes.
Values are in n (%), mean ± SD, or percent of total population. The following parameters had patients (n) with missing data: Weight, n = 192; BMI, n = 206; HbA1c, n = 119; FPG, n = 380; SBP/DBP, n = 210; Total cholesterol, n = 910; Triglycerides, n = 772; HDL-C, n = 1052; LDL-C, n = 538.
- ACEI
- angiotensin-converting-enzyme inhibitors
- ARB
- angiotensin II receptor blockers
- BMI
- body mass index
- CAD
- coronary artery disease
- DBP
- diastolic blood pressure
- DPP4
- dipeptidyl peptidase-4
- FPG
- fasting plasma glucose
- GLP-1 RA
- glucagon-like peptide-1 receptor agonists
- HbA1c
- glycated hemoglobin
- HDL-C
- high-density lipoprotein cholesterol
- LDL-C
- low-density lipoprotein cholesterol
- PAD
- peripheral artery disease
- SBP
- systolic blood pressure